Does bosutinib/bosutinib treat ALS?

Bosutinib/Bosutinib is a targeted therapy drug mainly used for certain types of leukemia. Its research in the treatment of ALS (ALS) is ongoing, but it has not yet been widely recognized. Amyotrophic lateral sclerosis, also known as amyotrophic lateral sclerosis, is caused by the gradual death of motor neurons, causing patients to experience progressive muscle weakness and atrophy, which seriously affects the quality of life.

APhase II clinical study shows that bosutinib may be helpful for ALS patients. In this study, the research team recruited 26 ALS patients and treated them with bosutinib for 24 weeks to observe its impact on disease progression. It is worth pointing out that at least 13 of these 26 patients were observed to have a slowdown in disease progression. Compared with the traditional treatment drug edaravone, bosutinib shows certain advantages in delaying the decline of ALSFRS-R score, which means that it may play a role in improving patients' motor function.

During the study, patients were divided into two groups, receiving 200 mg and 300 mg of bosutinib respectively. The results showed that in these two dose groups, the changes in ALSFRS-R scores were consistent with the 95% confidence interval, indicating that the results were highly reliable. In addition, the study also found that changes in patients' plasma NFL (neurofilament protein) levels before and after treatment have potential clinical significance. NFL is considered a biomarker for the progression of ALS.

Although the preliminary results look promising, it should be noted that the current application of bosutinib in the treatment of ALS is still in the exploratory stage, and a mature treatment plan has not yet been formed. Therefore, further clinical trials and data accumulation are crucial to confirm the efficacy and safety of bosutinib in the treatment of ALS.

Reference materials:https://sj.jst.go.jp/news/202408/n0801-01k.html